News

The U.S. Food and Drug Administration (FDA) has given Cabaletta Bio the go-ahead to launch a Phase 1/2 clinical trial testing its cell therapy CABA-201 in people with generalized myasthenia gravis (gMG). The upcoming trial is expected to enroll a dozen adults with gMG — six who are positive…

Both propofol and sevoflurane — two types of agents for anesthesia management — were found to be safe and effective when used without muscle relaxants in myasthenia gravis (MG) patients undergoing surgery to remove the thymus gland. These findings, involving patients at a hospital in Vietnam, highlight what researchers…

Negative emotions, a personality trait known as neuroticism, are more likely in people with myasthenia gravis (MG) than those without this disease, and may explain why these patients appear to be more liable to depression and anxiety, a study suggests. MG patients also scored lower than healthy adults for openness…

Women with myasthenia gravis (MG) have more severe disease and worse quality of life than men, according to a study in Germany, which also found overweight patients had poorer quality of life too. The delay in being diagnosed was also longer for women than for men, which may result…

People living with generalized myasthenia gravis (gMG) in the U.S. who experience certain barriers to healthcare reported major economic concerns in a new patient survey. These patients highlighted issues related to managing funds for emergency care, loss of income, and other non-medical expenses as contributing to a greater economic…

The U.S. Food and Drug Administration (FDA) has approved zilucoplan, a once-daily injection therapy to now be marketed under the brand name Zilbrysq, for adults with generalized myasthenia gravis (gMG) who are positive for antibodies targeting the acetylcholine receptor (AChR). With this approval, Zilbrysq has now become the…

Measuring how much immunoglobulin G (IgG) antibody levels drop after plasmapheresis, a blood-cleansing treatment for myasthenia gravis (MG), may help in determining the disease’s likely course, at least in the short term, a small study suggests. Changes in this potential biomarker that signal improvement also could help in…

Daily treatment with zilucoplan was tied to meaningful reductions in symptom severity among the subgroup of Japanese generalized myasthenia gravis (gMG) patients who participated in the Phase 3 RAISE clinical trial, according to new subgroup analyses. The data add to accumulating trial evidence that the UCB therapy…

About two years treatment with the immunosuppressant tacrolimus safely and effectively eases symptoms in children and adolescents with myasthenia gravis (MG) while cutting down the need for oral prednisone, according to a small study in China. Corticosteroids like prednisone, often used when other medications fail to control…

A treatment based on GRO Biosciences‘ ProGly program — which uses specially designed proteins to regulate the immune system — substantially reduced disease activity in an animal model of myasthenia gravis (MG), according to new data presented by the company. “We are greatly encouraged by the results of…